GlassScriptPhysician profile
Pradipkumar K Patel
NPI 1578506465
$3,211.14
in general payments reported to CMS, 2019-2025
35 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $362 · 2021: $347 · 2022: $461 · 2023: $632 · 2024: $389 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,439.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $671.22 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $505.10 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $213.69 | 2019-2025 | Prolia, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.71 | 2019-2022 | |
| Abbott Laboratories | $162.01 | 2019-2025 | Freestyle Libre 3, Octrode, Jot Dx |
| Amarin Pharma, INC. | $144.46 | 2019-2021 | |
| Abbvie INC. | $131.98 | 2020-2023 | |
| Pfizer INC. | $114.76 | 2019-2022 | |
| Novo Nordisk INC | $111.18 | 2019-2022 | |
| Glaxosmithkline, LLC. | $96.00 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $92.25 | 2024-2025 | Veozah |
| Nestle Healthcare Nutrition INC. | $66.83 | 2021-2022 | |
| Exact Sciences Corporation | $61.65 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $59.90 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.50 | 2023-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $54.88 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $54.03 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $48.23 | 2019 | |
| Edwards Lifesciences Corporation | $43.86 | 2022 | |
| Globus Medical, INC. | $43.17 | 2025 | Omnia, Senza |
| Xeris Pharmaceuticals, INC. | $41.79 | 2022-2023 | Gvoke Hypopen |
| Boston Scientific Corporation | $36.62 | 2019-2023 | |
| Allergan, INC. | $25.39 | 2020 | |
| Lucid Diagnostics INC. | $19.45 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.20 | 2022 | |
| Hikma Pharmaceuticals USA | $18.94 | 2020 | |
| Janssen Pharmaceuticals, INC | $17.48 | 2022 | |
| Emergent Biosolutions INC. | $16.91 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.63 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $16.47 | 2020 | |
| Seqirus USA INC | $16.12 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Currax Pharmaceuticals LLC | $14.30 | 2025 | Contrave |
| Depuy Synthes Sales INC. | $13.74 | 2019 | |
| Sk Life Science, INC. | $12.81 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradipkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.